Last reviewed · How we verify
NCT00666601
Microdialysis and Pharmacokinetic Study of TR-701
Phase 1 trial testing TR-700 (active moiety) in Healthy in 15 participants. Completed in 12 August 2008.
12 August 2008
Quick facts
| Lead sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 4 April 2008 |
| Primary completion | 12 August 2008 |
| Estimated completion | 12 August 2008 |
| Sites | 1 location across United States |
Drugs / interventions tested
- TR-700 (active moiety) — full drug profile →
- TR-701 (pro-drug) — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →
Who can join
Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00666601
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials
Trials by the same sponsor.
- NCT01623401 — A Phase 1, Open-Label, 10 Day Safety Study · Phase 1 · completed
- NCT01577459 — A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response · Phase 1 · completed
- NCT01519778 — A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study · Phase 2 · completed
- NCT01496677 — Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects · Phase 1 · completed
- NCT01461460 — A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00666601 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Last refreshed: 15 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00666601.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing